Laparoscopic vs. Open Distal Gastrectomy After Neoadjuvant Chemotherapy
NCT ID: NCT04658589
Last Updated: 2020-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
238 participants
INTERVENTIONAL
2021-01-31
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
238 patients with medically and technically operable advanced gastric adenocarcinoma in middle or distal 1/3 of stomach are enrolled and randomly assigned to laparoscopic gastrectomy group and open gastrectomy group. 4 cycles of mFLOT chemotherapy will be conducted before and after gastrectomy.
The primary objective of this study is comparison of D2 lymph node dissection compliance rate between open surgery group and laparoscopic surgery group after neoadjuvant chemotherapy.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
However, neither technical nor oncologic stability was established for laparoscopic gastrectomy surgery after neoadjuvant chemotherapy. Anticipated benefits from laparoscopic gastrectomy surgery after neoadjuvant chemotherapy are as follows: 1) Reduced postoperative complications; 2) Reduced intra- or postoperative transfusion and patient's pain after surgery; 3) Enhance postoperative recovery (shortened hospitalization duration); 4) Facilitate completion rate of adjuvant chemotherapy.
The study was designed as single-country, multi-center, open-labelled, randomized (1:1), phase II trial.
238 patients with medically and technically operable advanced gastric adenocarcinoma in middle or distal 1/3 of stomach are enrolled and randomly assigned to laparoscopic gastrectomy group and open gastrectomy group. 4 cycles of mFLOT chemotherapy will be conducted before and after gastrectomy.
The primary objective of this study is comparison of D2 lymph node dissection compliance rate between open surgery group and laparoscopic surgery group after neoadjuvant chemotherapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Laparoscopic distal gastrectomy
Laparoscopic distal gastrectomy after neoadjuvant chemotherapy for the treatment of locally advanced gastric cancer patients
Laparoscopic versus open distal gastrectomy
Laparoscopic versus open distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer
Open distal gastrectomy
Open distal gastrectomy after neoadjuvant chemotherapy for the treatment of locally advanced gastric cancer patients
Laparoscopic versus open distal gastrectomy
Laparoscopic versus open distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Laparoscopic versus open distal gastrectomy
Laparoscopic versus open distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients whose gastric adenocarcinoma located in the middle or lower part of the stomach is histologically confirmed and deemed possible to perform a radical distal gastrectomy surgery.
3. Patients who come under T2/N(+)M0, T3\~4a/N(- or +) M0 according to the 8th edition of the TNM classification.
Exclusion Criteria
1. Patients less than 20 years old or older than 80 years old
2. Eastern Cooperative Oncology Group(ECOG) ≥ 2
3. Patients with a surgery experience due to a neoplasm in the stomach.
4. Patients with complications due to gastric cancer (acute hemorrhage, gastric outlet obstruction or perforation)
5. Patients with distant metastases (M1) including distant lymph nodes (Retropancreatic, para-aortic, periportal, retroperitoneal, or mesenteric lymph nodes)
6. Patients without distant metastases but who are, according to a surgeon's judgment, unqualified for radical gastrectomy because of invasions to adjacent organs (T4b).
7. In the case of localized conglomerated metastatic lymph nodes
8. Patients who received surgery or radiation therapy for a primary cancer developed in another organ or those with active/synchronous double cancer in recent 5 years.
9. Patients who participated in another clinical trial or was administered with a different investigational drug in 30 days prior to randomization.
10. Patients who had any of the following in 6 months before the trial recruitment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass surgery, NYHA class III or IV congestive heart failure, stroke or transient ischemic attack.
11. Patients with a previous experience of uncontrolled seizure, central nervous system or psychological disorders whose conditions are clinically significant to the extent that they are unable to express consent to participate in the trial and oral drug administration is not possible.
12. Patients with uncontrolled active infection or sepsis.
13. Patients who had deep vein thrombosis in recent 4 weeks before the beginning of the trial recruitment.
14. Patients with serious acute or chronic disease that can degrade the patient's ability to participate in the trial or impede the interpretation of the trial results.
15. Pregnant or breast-feeding patients. Fertile female patients who are positive in pregnancy test.
Drug Administration for Neoadjuvant Chemotherapy
16. Inadequate functions of marrow or organs:
I. Absolute Neutrophil Count (ANC) \< 1.5 x 109/L II. Platelet (PLT) \< 100 x 109/L III. Hemoglobin (Hb) ≤ 9 g/dL IV. AST\> 2.5 x ULN, ALT\> 2.5 x ULN V. ALP \> 2.5 x ULN VI. Total Bilirubin (T. Bil) \> 1.5 x ULN VII. Serum creatinine (Cr) \> 1.5 x ULN
17. Patients who have peripheral neuropathy with clinical signs of Grade≥2 (NCI CTCAE v4.03) or with absence of deep tension reflex (DTR).
18. Patients with hypersensitivity history of the investigational drug (5-FU, Oxaliplatin, Docetaxel).
19. Patients who are on treatment with warfarin or coumarin anticoagulants.
20. Patients who are on immunosuppressive therapy.
21. Patients who are receiving co-medication with Cytochrome P450 2A6 inducer, inhibitor, and substrate.
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chonnam National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Young Kyu Park
Professor
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H2020-0407
Identifier Type: -
Identifier Source: org_study_id